Get started
ADMA Biologics IncADMA Biologics IncADMA Biologics Inc

ADMA Biologics Inc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ADMA trade ideas

Market update 6/2/2024Just going through the usual updates. I'm mostly doing these videos for myself kind of like a trading journal and also to look back on it later whether I was right or wrong about some things. I don't have notes and I completely improvise it so I probably misspeak sometimes, also that's why there's no structure to what I'm saying, I just talk about what comes to mind. I also want to keep track of my performance, my mindset and the rationale for the trades I'm making. I've been recording these every week for 2 months now but only decided last week to start making them public, so will keep doing that. Not sure if anyone will find it useful, but if I ever become rich, at least I have proof. And if I don't make it and I go broke, then you can also learn from me which is what not to do! But in general, these will probably keep me accountable and disciplined, so I like publishing these.
NASDAQ:ADMA
by BenedekBokor
ADMA daily reversal on high volumeDaily price candle reversal to the upside on a 3X daily average volume (due to a large 2M buy order at 12:10pm EST) at major demand zone $3.20 - $3.37. Double digit y-o-y revenue growth, improving quarterly earnings (EPS loss decreasing), EPS to turn positive by end 2024 or early 2025. Next catalyst is the Q3 earnings release in early Nov. Related sector is Biotech. Using XBI ETF as reference, the sector is in the process of bottoming on high volume with positive divergence with RSI, although this process is not yet completed. A more conservative time for entry is to wait till next week for signs of positive price momentum to show up in the weekly candlestick.
NASDAQ:ADMALong
by tanjunse
Long Preferred Stock The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at September 30, 2021 and December 31, 2020. Common Stock As of September 30, 2021 and December 31, 2020, the Company was authorized to issue 300,000,000 and 150,000,000 shares, respectively, of its common stock, $0.0001 par value per share, and 138,313,817 and 104,902,888 shares of common stock were outstanding as of September 30, 2021 and December 31, 2020, respectively. On May 27, 2021, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation which increased the number of shares of common stock that the Company is authorized to issue from 150,000,000 to 300,000,000. After giving effect to the 16,828,915 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company’s equity incentive plans, as of September 30, 2021 there were 144,641,489 shares of common stock available for issuance. On August 5, 2020, the Company entered into an open market sale agreement (as amended from time to time, the “Sale Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company could offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50 million of shares of the Company’s common stock. On November 5, 2020 and February 3, 2021, the Company and Jefferies amended the Sale Agreement to provide for increases in the aggregate offering amount under the Sale Agreement such that the Company could sell shares having an aggregate offering price of up to $105.4 million under the Sale Agreement, as amended. During the nine months ended September 30, 2021, the Company issued and sold 27,805,198 shares of common stock under the 2020 Sale Agreement and received net proceeds of $60.4 million. The Sale Agreement was terminated on August 31, 2021. Sec.gov On September 3, 2021, the Company entered into a distribution agreement with Raymond James & Associates, Inc., as agent (“Agent”), pursuant to which the Company may offer and sell, from time to time, at its option, through or to the Agent, up to an aggregate of $50 million of shares of the Company’s common stock (the “Distribution Agreement”). The Company currently intends to use any net proceeds from the sale of its common stock under the Distribution Agreement for general corporate purposes, including procurement of raw materials, source plasma, supply chain initiatives and production expenditures, funding expansion of plasma centers, working capital, capital expenditures, expansion and resources for commercialization activities, and other potential research and development and business opportunities. During the nine months ended September 30, 2021, the Company issued 5,540,831 shares of its common stock under the Distribution Agreement and received net proceeds of $6.9 million. On February 11, 2020, the Company completed an underwritten public offering of 23,500,000 shares of its common stock for gross proceeds of $82.3 million. On February 21, 2020, the Company sold an additional 3,525,000 shares pursuant to the underwriters’ exercise of their option to purchase additional shares of the Company’s common stock for additional gross proceeds of $12.3 million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7 million. Warrants At September 30, 2021 and December 31, 2020, the Company had outstanding warrants to purchase an aggregate of 4,528,160 shares of common stock, with a weighted average exercise price of $2.82 per share and expiration dates ranging between June 2022 and December 2030.
NASDAQ:ADMALong
by Susan1979
2024 long SEC.gov The Company believes that a debt refinancing and expansion of its current debt facility, combined with the proceeds received from the foregoing public offering further discussed in Note 14, will be sufficient to fund its operations into the first quarter of 2024, at which time the Company believes its operations will be cash-flow positive. The Company is also evaluating a variety of strategic and financing alternatives and has engaged Morgan Stanley as a financial advisor in connection with certain of those strategic alternatives. There can be no assurances that the Company will be able to successfully refinance or expand its existing debt to obtain additional non-dilutive financing. These estimates may change based upon several factors, including the success of the Company’s commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA’s immune globulin products by physicians, patients, or payers and the various financing options that may be available to the Company.
NASDAQ:ADMALong
by Susan1979
ADMA at 50 on Fib RetracementADMA is hovering around the 50 retracements with a lot of sell orders on the books probably from people trying to get out at 1.90. Buy orders look good though in the face of this massive sell-off. This is was after news dropped that analysts saw the price between 6 and 11 dollars. Although ADMA has been struggling to turn a profit most of these reasons have been to position themselves for the infrastructure necessary to start pulling in good returns. This FDA approval is looking more and more like the catalyst necessary to break through 3 dollars.
NASDAQ:ADMALong
by DiastoAle
ADMA Technical Analysis 🧙ADMA Biologics Inc is a United States-based biopharmaceutical company. It is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The operating segments of the company are ADMA BioManufacturing segment; Plasma Collection Centers segment; and Corporate segment. The Plasma Collection Centers segment consists of three FDA-licensed source plasma collection facilities located in Georgia. The company's ADMA BioManufacturing segment reflects the company's immune globulin manufacturing and development operations in Florida. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ADMALong
by yura_trades